您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2021 - 07 - 09
点击次数: 0
所属职位: 创始人,董事长
所属公司: 天境生物科技(上海)有限公司
个人简介:
臧敬五博士于2016年创立天境生物,现任天境生物董事长。在他的领导下,天境生物在短短五年内迅速建立起拥有十多个具有全球竞争力的创新药研发管线,并成功在美国纳斯达克上市,天境生物目前正快速成长为覆盖全产业链的综合性全球生物制药公司。臧敬五博士曾先后在跨国医药公司和中国药企担任高级管理职务, 包括葛兰素史克(GSK)全球高级副总裁兼全球神经系统治疗领域负责人及中国研发中心负责人,先声药业集团首席科学官和百家汇总裁。在进入药企之前,臧敬五博士曾任美国贝勒医学院(Baylor College of Medicine)免疫学及神经学教授。回国后,臧敬五博士参与创建了中国科学院健康科学研究所和上海巴斯德研究所并担任两家研究所的首任所长,他还曾任上海市免疫学研究所所长、上海交大医学院基础医学院院长等职务。臧敬五博士毕业于上海第二医科大学(现上海交通大学医学院),布鲁塞尔大学免疫学博士,美国哈佛医学院免疫学博士后。在国际顶尖和知名学术期刊上共发表130余篇论文、综述及专著。臧敬五博士在美国贝勒医学院完成住院医师规培并持美国德州职业医师执照(Texas Medical Board)。 Dr. Zang founded I-Mab in 2016 and brought the Company to NASDAQ in early 2020. Under his leadership, I-Mab has evolved from an early-stage discovery company into a clinical stage company with an innovative and globally competitive pipeline in only four years.Prior to founding I-Mab, Dr. Zang held various senior executive positions in global and China pharma groups, including Senior Vice President and head of Neuroscience Therapeutic Area and head of China R&D Center with GlaxoSmithKline and Chief Scientific Officer and President with Simcere Pharmaceuticals and BioSciKin, an innovative drug development platform.Dr. Zang started his academic pursuit at Dr. L. Willems Institute in Belgium where he was head of multiple sclerosis research unit and later became Professor of Neurology and Immunology and Research Director of Multiple Sclerosis Center at Baylor College of Medicine in US. During his academic career in China, Dr. Zang founded the Institute of Health Sciences and co-founded the Institute Pasteur Shanghai with the Chinese Academy of Sciences. He also served as Dean of School of Medical Sciences at the Shanghai JiaoTong University and Director of Shanghai Institute of Immunology. Dr. Zang published more than 130 scientific articles and book chapters in prestigious journals and publications, including in Science, Nature Medicine, Nature Immunology, Immunity.Dr. Zang received his medical degree from Shanghai JiaoTong University School of Medicine, Ph.D. in Immunology from University of Brussels and completed his postdoctoral fellowship at Harvard Medical School. Dr. Zang is a licensed physician (Texas Medical Board) in US.
发布时间: 2021 - 07 - 09
点击次数: 0
所属职位: 董事长、CEO
所属公司: 创响生物
个人简介:
王健博士拥有逾30年生物医疗健康领域的创业、投资、金融及科研经验。他在诺贝尔奖得主Eric Kandel的指导下获得哥伦比亚大学神经生物学博士学位,曾荣获Howard Hughes Medical Institute(HHMI)科研奖金,并拥有斯坦福大学MBA。 王博士是创响生物的董事长和CEO。创响是一家在免疫相关新药研发领域处于领先地位的生物技术公司,在圣地亚哥、上海、杭州和武汉拥有全资子公司。该公司已融资1.4亿美元,正在打造一个拥有十余个产品的强大管线,其中最成熟的候选药物IMG-020即将针对5种适应症进入全球2或3期临床试验。 王博士曾是全球最大的专注于生物医疗的投资公司奥博资本(OrbiMed)的全球合伙人及奥博亚洲(OrbiMed Asia)创始合伙人,在奥博的12年间,他联合创建并管理了11亿美元的PE/VC基金,曾被评为中国生物医疗投资Top10。他曾孵化了冠科美博(Apollomics)和Bridge(后被收购),并曾任冠科美博及时代天使公司的董事长。 他是百华协会(BayHelix,中国生物医疗商业领导者的组织)的联合创始人及前任主席,也是香港股票交易所生物科技咨询小组成员。王博士以笔名光子著有《世界边缘的秘密》《我∙世界》等科学哲学著作。Dr. Jonathan Wang has over 30 years of healthcare and life sciences experience, spanning entrepreneurship, investment, research, and finance. Under the supervision of Eric Kandel, a Nobel Laureate, he obtained a Ph.D. in Neurobiology from Columbia University where he was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship. He also earned an MBA from Stanford University. Dr. Wang is the Chairman and CEO of Inmagene, a leading clinical-stage biotech company focused on immunology-related therapeutic areas.  With wholly owned subsidiaries in San Diego, Shanghai, Hangzhou and Wuhan, the company has raised approximately $140M financing and is building a strong pipeline with over 10 drug candidates. The lead drug candidate, IMG-020, is about to enter global phase 2 or 3 trials for 5 autoimmune indications. Dr. Wang was a Partner at OrbiMed, the world’s largest healthcare-dedicated investment firm.  He co-founded OrbiMed Asia where he led the establishment and management of $1.1B PE/VE funds.  He was named one of the top 10 healthcare investors in China.  He incubated Apollomics and Bridge (acquired), and served as Chairman at Apollomics and Angelalign.He is a HKEX Biotech Advisory Panel member and a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders.  He has authored two philosophy of science books.
发布时间: 2021 - 07 - 09
点击次数: 0
所属职位: 执行总裁,全球研发总裁,兼CMO
所属公司: 复星医药
个人简介:
回爱民博士,复星医药执行总裁,全球研发总裁,首席医学官。现兼任上海市干细胞治疗重点实验室主任,中国药促会肿瘤学委员会副主任。曾担任赛诺菲全球临床研发副总裁, 第五届中国肿瘤学术大会学术委员会副主任。亲自领导了Izaxomib,Isatuximab等多个小分子及生物制剂抗癌药的全球研发,注册,上市。主导了伊莎咗咪,阿伐曲珀帕等多款创新药在中国的研发注册上市。在新英格兰医学杂志,自然医学,柳叶刀,细胞癌症等发表论文八十余篇。最近主导了复星医药与BioNTech合作mRNA新冠疫苗项目协约签署及大中华区域研发,注册(港澳已上市)。 Dr. Aimin Hui is the Executive President of Fosun Pharma, President of Global R&D, and Chief Medical Officer. He is currently the Director of Shanghai Key Laboratory of Stem Cell Therapy and the Deputy Director of the Oncology Committee of China Pharmaceutical Association. He was the Vice President of Global Clinical R&D of Sanofi and the Vice Chairman of the Academic Committee of the 5th China Academic Oncology Conference. He has led the global development, registration and marketing of several small molecule and biologic anti-cancer drugs such as Izaxomib and Isatuximab. He has led the development and registration of several innovative drugs such as Ixazomib and Avatrombopag in China. He has published more than 80 papers in New England Journal of Medicine, Nature Medicine, Lancet, Cell Cancer, etc. Recently, he led the collaboration between Fosun and BioNTech on the development and registration of mRNA vaccines in Greater China (already marketed in Hong Kong and Macau).
发布时间: 2021 - 07 - 09
点击次数: 0
所属职位: BD负责人
所属公司: 江苏康宁杰瑞生物制药有限公司
个人简介:
在医药行业拥有超过10年商务拓展、战略及联盟管理、市场营销经验,此前曾在就职于全球知名药企诺华、强生、勃林格以及卫材,曾参与并领导完成多项许可交易、战略合作、股权投资等项目,在商务拓展价值链的各个环节都具有丰富的经验,熟悉肿瘤免疫、神经、呼吸及消化领域。获得中国科学院生物医药专业硕士和山东大学生物技术学士学位。 With over 10 years of  pharmaceutical industry experience in business development, strategy & alliance management, sales & marketing, had served various positions in many global leading pharma companies including Novartis, Johnson & Johnson, Boehringer Ingelheim and Eisai, led to complete a number of licensing deals, strategic cooperation and equity investment projects, owned a wealth of experience across all parts of business development value chain, familiar with immunology, neurology, respiratory and digestive fields. He has received a master's degree in biomedicine from the China Academy of Science and a bachelor's degree in biotechnology from Shandong University.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务